In vitro studies suggest that nucleoside analogs have an antipatients with CML in chronic (n = 11) or accelerated (n = 1) leukemic effect against chronic myelogenous leukemia (CML).
Introduction
Patients treated with DCF received 4 mg/m 2 over 1 h every week for 4 weeks, followed by every other week for four The nucleoside analogs, 2′-deoxycoformycin (Pentostatin; doses, and then maintenance with the same dose given once DCF), fludarabine (2-fluoro-ara-AMP; FAMP), and 2′-chloroa month. Patients treated with fludarabine received deoxyadenosine (Cladribine; 2-CdA), have been extensively 30 mg/m 2 /day for 5 days every 28 days. In both programs, studied in recent years and have shown activity in a growing therapy was continued until evidence of disease progression number of lymphoproliferative malignancies, most notably or significant toxicity. A bone marrow aspirate and complete chronic lymphocytic leukemia, hairy cell leukemia, low-grade blood counts were performed prior to the start of therapy. lymphomas, Wäldenstrom macroglobulinemia, and prolymPeripheral blood counts were monitored once or twice weekly phocytic leukemia. [1] [2] [3] The activity of nucleoside analogs has for 2 months, and then every 2-4 weeks. also been investigated in myeloid malignancies. Several investigators reported complete responses in patients with refractory or relapsed acute myelogenous leukemia treated with fludarabine. [4] [5] [6] Unfortunately, the doses required to achieve
Response criteria responses were associated with severe neurotoxicity. 4-6 2-CdA has also shown significant antileukemic activity in acute
Patients were considered to have antileukemia effect if there myelogenous leukemia in children, 7, 8 but not in adults. 9, 10 was at least a 25% decrease in the WBC count for a minimum Interest in the effect of nucleoside analogs in chronic of 3 months for patients in chronic phase, or resolution of myelogenous leukemia (CML) stems from in vitro studies accelerated phase features for patients in accelerated phase.
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showing that nucleoside analogs can selectively suppress in A complete hematologic remission was defined as a normalizvitro proliferation, 11 and induce apoptosis 12 of CML cells. ation of the bone marrow, with Ͻ5% blasts, and of peripheral Saven et al 13 reported hematologic responses in 83% of blood with WBC less than 10 × 10 9 /l, and no blasts, promyelocytes, or myelocytes in the peripheral blood, together with disappearance of all signs and symptoms of the disease. A partial response was defined as normalization of bone marrow promyelocytes, or myelocytes in the peripheral blood, and at least a 50% decrease in spleen size. 16 
Results

Deoxycoformycin (DCF)
A total of four patients were treated with DCF (Table 1) . Their median age was 44.5 years (range 17-54 years); two were females. All had Philadelphia chromosome (Ph)-positive disease. Two patients were in late chronic phase, and two in accelerated phase on the basis of clonal evolution (trisomy 8, and double Ph, respectively). All patients had been previously treated with at least two prior treatment regimens, and all had received and were refractory to prior therapy with interferon alpha. count while on the induction phase of therapy (ie weekly schedule), but in all cases, the WBC rapidly increased when was nausea and vomiting, which was present in all patients switched to the every other week schedule. In all three during therapy. It was mild in three patients, and moderate in patients the increase in WBC resulted in counts significantly one. One patient had an elevated blood pressure to higher than the baseline counts before the start of therapy with 150/100 mmHg which returned to normal after discontinu-DCF. A reinduction phase with every week doses again conation of DCF. trolled the counts, but in none of these patients could the WBC count be controlled with less frequent therapy. Figure 1 shows a representative case of this pattern (patient 1). The Fludarabine fourth patient had no response to the induction weekly schedule, and was taken off protocol.
Nine patients were treated with fludarabine (Table 1) . Their median age was 57 years (range 33-72 years), and six were Therapy was well tolerated. The most significant side-effect female. Three had Ph-positive disease, and six were Ph-negapression was achieved in most patients with both drugs, there tive: three of them had no rearrangement of the bcr gene (Phwas no evidence of a significant durable antileukemic effect, negative, bcr-negative), and in three this information was not and no evidence of a cytogenetic response. This is similar to available. Four patients were in late chronic phase and five the observation with other chemotherapeutic agents such as in accelerated phase. All patients had been previously treated: busulfan or hydroxyurea, which produce no cytogenetic two had received one prior therapy regimen, three had responses despite adequate control of the hematologic manireceived two regimens, and four had received three or more festations of the disease. 17 Moreover, with deoxycoformycin prior regimens. Six patients had received and were refractory and fludarabine, the hematologic control was only transient, to prior therapy with interferon alpha; the three patients not and sometimes followed by a rebound leukocytosis to values previously treated with interferon alpha had either Ph-negative higher than pre-treatment levels. disease in late chronic phase (two patients), or Ph-positive disSimilar results have been obtained with 2-chlorodeoxyease in accelerated phase (one patient).
adenosine (2-CdA). Saven et al 13 treated 12 patients with PhPatients received a median of two courses of therapy (range positive CML (11 in chronic phase and one in accelerated 1-4). In all cases fludarabine produced a transient reduction phase) with 2-CdA at 0.1 mg/kg/day by continuous infusion of WBC counts. The WBC counts reached a median nadir of for 7 days. All patients had a decrease in WBC counts, but 1.4 × 10 9 /l (range 0.1-9.7 ϫ 10 9 /l). However, no patient this was transient with a median duration of hematologic achieved significant antileukemic effect as defined earlier.
response of 3 months. Several patients required platelet apherTwo patients in accelerated phase (patients 5 and 8) proesis, leukapheresis, or hydroxyurea between courses of 2-CdA gressed to blastic phase as the patients recovered from the first to maintain their WBC counts. 13 None of the 12 patients course of fludarabine therapy (day 20 and day 57 of the first treated achieved a cytogenetic response, and immunosupprescourse, respectively). Two other patients (patients 12 and 13) sion associated with opportunistic infections was seen in four died early in the course of therapy. Both were in accelerated patients. 13 Marks et al 14 treated 10 patients with accelerated phase by virtue of low platelet count at the start of therapy or blastic phase CML with 2-CdA at dosages of 6-(platelet count 9 × 10 9 /l and 4 × 10 9 /l, respectively), and died 12 mg/m 2 /day. Six patients had been previously treated with of hemorrhagic complications on day 9 of course 1, and day other agents. Only one patient responded, achieving a partial 35 of course 2, respectively. The other five patients had transiresponse that lasted 9 months, without cytogenetic ent decrease in WBC counts which recovered to pre-treatment remission.
14 Six patients had neutropenia and fever, but none values or higher. Figure 2 shows a representative course of had documented infections.
14 therapy with fludarabine (patient 10). The median time to the In vitro studies suggested that nucleoside analogs have a second course of therapy with fludarabine or other therapy in selective antileukemic effect against CML. 2-CdA was these patients was 24 days (median 21-39 days). There were reported to have greater suppressive effect on the growth of no cytogenetic responses. cultured bone marrow cells from patients with CML than in The only significant toxicity was hematologic, with thrombone marrow cells from normal controls. 11 Zinzani et al 12 bocytopenia and hemorrhage in three patients. As mentioned, investigated the effect of fludarabine on induction of apoptosis two patients died from hemorrhage. Two patients had fever in peripheral blood mononuclear cells from patients with while neutropenic and required hospitalization for intra-CML. Apoptosis was induced when cells were incubated with venous antibiotics, but recovered from this complication.
fludarabine in patients with CML, but not in normal controls.
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It has been suggested that the nucleoside analogs may be used in combination with other agents in the therapy of CML.
Discussion
In vitro studies show an additive effect of 2-CdA and interferon-alpha on inhibiting the growth of CFU-GM cells from The results from this study suggest that nucleoside analogs patients with CML compared to those from normal controls. 19-21 Profound lymphocytopenia is seen in most patients treated with these drugs, with a significant decrease in CD4 + lymphocytes which may last for several years after therapy.
21 This is frequently associated with opportunistic infections. [19] [20] [21] It is possible that the immunosuppression may contribute to worsening of the CML process, since immune mechanisms may be partly responsible for its control, particularly after therapy with interferon-alpha or bone marrow transplantation. 22 In this context, six patients in this study had a rebound in WBC counts after therapy, with post-treatment WBC counts higher than pretreatment values, and two patients rapidly progressed to a blastic phase.
In conclusion, the results of the present trial, together with previous experience with 2-CDA, suggest that nucleoside analogs may not have a significant role in the management of CML. The lack of correlation of in vitro and in vivo results,
Figure 2
Course of WBC counts on patient 10 while on therapy with fludarabine.
and the clinical experience should lead to a cautious
